Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China SFDA Streamlines Approval Process For AIDS, Cancer Drug Imports (China)

This article was originally published in PharmAsia News

Executive Summary

China's State FDA says it is taking steps to remove some of the country's barriers to importation of cancer drugs, and of HIV/AIDS drugs in the wake of new infection figures. Drug registration Director Zhang Wei said the SFDA has adopted a streamlined approach to approving imports of drugs in the two categories, if they demonstrate significant clinical effects in treating disease. Under the policy, the agency cuts its 150 working days for approving most drugs to just 120 for an AIDS drug. Zhang also said U.S. company Gilead's Viread (tenofovir disoproxil fumarate) second-line anti-retroviral drug cocktail is under review. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts